首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   33391篇
  免费   2221篇
  国内免费   127篇
耳鼻咽喉   415篇
儿科学   717篇
妇产科学   391篇
基础医学   4361篇
口腔科学   522篇
临床医学   3622篇
内科学   6771篇
皮肤病学   490篇
神经病学   2732篇
特种医学   1389篇
外科学   5820篇
综合类   290篇
一般理论   38篇
预防医学   2517篇
眼科学   765篇
药学   2225篇
中国医学   23篇
肿瘤学   2651篇
  2024年   38篇
  2023年   206篇
  2022年   352篇
  2021年   880篇
  2020年   515篇
  2019年   797篇
  2018年   918篇
  2017年   716篇
  2016年   765篇
  2015年   834篇
  2014年   1325篇
  2013年   1550篇
  2012年   2708篇
  2011年   2679篇
  2010年   1497篇
  2009年   1230篇
  2008年   2249篇
  2007年   2395篇
  2006年   2297篇
  2005年   2332篇
  2004年   2121篇
  2003年   1984篇
  2002年   1896篇
  2001年   253篇
  2000年   156篇
  1999年   242篇
  1998年   387篇
  1997年   286篇
  1996年   225篇
  1995年   281篇
  1994年   173篇
  1993年   162篇
  1992年   112篇
  1991年   103篇
  1990年   76篇
  1989年   75篇
  1988年   69篇
  1987年   62篇
  1986年   77篇
  1985年   62篇
  1984年   82篇
  1983年   75篇
  1982年   93篇
  1981年   78篇
  1980年   73篇
  1979年   35篇
  1978年   31篇
  1977年   40篇
  1975年   23篇
  1974年   25篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
992.
The objective of this study was to determine the effects of oral sumatriptan on growth hormone (GH) release throughout the menstrual cycle in healthy female volunteers. A placebo-controlled cross-over design was employed. Subjects were tested a total of six times over two consecutive menstrual cycles; twice in the early follicular phase, twice in midcycle and twice in the late luteal phase. Oral sumatriptan (100 mg) and placebo were administered on alternate visits. Twelve healthy female volunteers aged between 18-40 years with regular menses and not taking oral contraceptives were recruited. Baseline blood samples at 0 min were taken for GH, oestrogen and progesterone estimation. GH was measured at +60, +90, +120 and +180 min following administration of oral sumatriptan 100 mg or matched placebo. GH, progesterone and oestrogen were measured by radioimmunoassay. At each phase of the menstrual cycle serum GH levels peaked at 60-90 min following administration of oral sumatriptan compared to placebo which showed no response. Analysing GH response to sumatriptan and placebo over time for the three phases of the menstrual cycle (three-way ANOVA) demonstrates that the GH response to sumatriptan did not alter.  相似文献   
993.
The Michigan Children's Trust Fund (MCTF) funds child abuse and neglect prevention programs and consults with community and clinical psychologists to oversee its research efforts. This paper highlights the role of community psychologists in this capacity and documents the effectiveness of this relationship through an example of the work they are asked to perform. The primary source of funding for MCTF is a voluntary donation line on Michigan's state income tax form. Because even modest changes in the percentage donating have bearing on funding, MCTF sought a greater understanding of forces affecting donations. Given that one half of all tax forms in Michigan are prepared professionally, an exploratory survey of preparers was undertaken. Results found preparers approved of raising money via the checkoff and were aware of MCTF, although they confused it with other social programs. Differences were found in knowledge and practices toward MCTF based on degree of approval of use of the tax checkoff, and the age, parental status, and gender of the preparer. These findings were important to MCTF in directing efforts to educate a segment of the population that has influence over the major source of their funding, and may be relevant to other organizations that depend on tax checkoffs for their income.  相似文献   
994.
In order to examine the eating behavior of individuals with the newly proposed diagnosis, binge eating disorder (BED), standardized meals were served to 20 obese women, 10 with BED and 10 without BED. When asked to binge eat from a multiple-item array of foods, obese subjects with BED consumed significantly more calories than did obese subjects without BED. Significant differences between the two groups were also found on several of the self-report measures. © 1993 by John Wiley & Sons, Inc.  相似文献   
995.
Overconcern with shape and weight is considered a primary feature of the psychopathology of bulimia nervosa and was included as a diagnostic criterion in DSM- III-R. In order to test the significance of shape and weight concern in bulimia nervosa, we administered the Body Shape Questionnaire (BSQ) to 78 outpatients with bulimia nervosa and three comparison groups: 14 women with seasonal affective disorder (SAD), 10 acquaintances of patients, and 32 normal controls. Women with bulimia nervosa had significantly higher mean BSQ scores than did other subject groups. Other self-report measures of body shape concern, eating attitudes, and depression were correlated with BSQ score. Furthermore, all patients had BSQ scores greater than the average score of the normal control group. These data support the continued inclusion of body shape and weight overconcern as a diagnostic criterion for bulimia nervosa but suggest that “overconcern” should be interpreted as “above average” rather than “outside the normal range”.  相似文献   
996.
997.
998.
The majority of colorectal cancer patients are not responsive to immune checkpoint blockade (ICB). The interferon gamma (IFNγ) signaling pathway drives spontaneous and ICB-induced antitumor immunity. In this review, we summarize recent advances in the epigenetic, genetic, and functional integrity of the IFNγ signaling pathway in the colorectal cancer microenvironment and its immunological relevance in the therapeutic efficacy of and resistance to ICB. Moreover, we discuss how to target IFNγ signaling to inform novel clinical trials to treat patients with colorectal cancer.  相似文献   
999.
BackgroundHeadache disorders are disabling, with major consequences for productivity, yet the literature is silent on the relationship between headache-attributed disability and lost productivity, often erroneously regarding the two as synonymous. We evaluated the relationship empirically, having earlier found that investment in structured headache services would be cost saving, not merely cost-effective, if reductions in headache-attributed disability led to > 20% pro rata recovery of lost productivity.MethodsWe used individual participant data from Global Campaign population-based studies conducted in China, Ethiopia, India, Nepal, Pakistan and Russia, and from Eurolight in Lithuania, Luxembourg and Spain. We assessed relationships in migraine and probable medication-overuse headache (pMOH), the most disabling common headache disorders. Available symptom data included headache frequency, usual duration and usual intensity. We used frequency and duration to estimate proportion of time in ictal state (pTIS). Disability, in the sense used by the Global Burden of Disease study, was measured as the product of pTIS and disability weight for the ictal state. Impairment was measured as pTIS * intensity. Lost productivity was measured as lost days (absence or < 50% productivity) from paid work and corresponding losses from household work over the preceding 3 months. We used Spearman correlation and linear regression analyses.ResultsFor migraine, in a linear model, we found positive associations with lost paid worktime, significant (p < 0.05) in many countries and highly significant (p < 0.001) in some despite low values of R2 (0–0.16) due to high variance. With lost household worktime and total lost productivity (paid + household), associations were highly significant in almost all countries, although still with low R2 (0.04–0.22). Applying the regression equations for each country to the population mean migraine-attributed disability, we found pro rata recoveries of lost productivity in the range 16–56% (> 20% in all countries but Pakistan). Analysing impairment rather than disability increased variability. For pMOH, with smaller numbers, associations were generally weaker, occasionally negative and mostly not significant.ConclusionRelief of disability through effective treatment of migraine is expected, in most countries, to recover > 20% pro rata of lost productivity, above the threshold for investment in structured headache services to be cost saving.  相似文献   
1000.
BackgroundTrust in healthcare providers is associated with important outcomes, but has primarily been assessed in the outpatient setting. It is largely unknown how hospitalized patients conceptualize trust in their providers.ObjectiveTo examine the dimensionality of a measure of trust in the inpatient setting.DesignExploratory factor analysis (EFA) and confirmatory factor analysis (CFA).ParticipantsHospitalized patients (N = 1756; 76% response rate) across six hospitals in the midwestern USA. The sample was randomly split such that approximately one half was used in the EFA, and the other half in the CFA.Main MeasuresThe Trust in Physician Scale, adapted for inpatient care.Key ResultsBased on the Kaiser-Guttman criterion and parallel analysis, EFAs were inconclusive, indicating that trust may be comprised of either one or two factors in this sample. In follow-up CFAs, a 2-factor model fit best based on a chi-squared difference test (Δχ2 = 151.48(1), p < .001) and a Comparative Fit Index (CFI) difference test (CFI difference = .03). The overall fit for the 2-factor CFA model was good (χ2 = 293.56, df = 43, p < .01; CFI = .95; RMSEA = .081 [90% confidence interval = .072–.090]; TLI = .93; SRMR = .04). Items loaded onto two factors related to cognitive (i.e., whether patients view providers as competent) and affective (i.e., whether patients view that providers care for them) dimensions of trust.ConclusionsWhile measures of trust in the outpatient setting have been validated as unidimensional, in the inpatient setting, trust appears to be composed of two factors: cognitive and affective trust. This provides initial evidence that inpatient providers may need to work to ensure patients see them as both competent and caring in order to gain their trust.KEY WORDS: trust, trust in physician scale, psychometrics  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号